CN Patent

CN120813385A — 通过施用配体-药物偶联体治疗卵巢癌

Assigned to Tong Yi Medicine Suzhou Co ltd · Expires 2025-10-17 · 1y expired

What this patent protects

本发明涉及一种配体‑药物偶联体在治疗卵巢癌中的用途，进一步，本发明涉及配体‑药物偶联体在制备用于治疗铂耐药的卵巢透明细胞癌的药物中的用途。

USPTO Abstract

本发明涉及一种配体‑药物偶联体在治疗卵巢癌中的用途，进一步，本发明涉及配体‑药物偶联体在制备用于治疗铂耐药的卵巢透明细胞癌的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN120813385A
Jurisdiction
CN
Classification
—
Expires
2025-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Tong Yi Medicine Suzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.